来氟米特联合缬沙坦治疗糖尿病肾病的临床研究

Clinical study on the treatment of diabetic nephropathy by flurmitate combined with valsartan

目的:研究来氟米特联合缬沙坦治疗糖尿病肾病的临床效果。方法:选择2015年1月~2017年5月于我院就诊的96例糖尿病肾病患者为研究对象,随机将所有患者分为对照组和研究组,各48例。对照组给予缬沙坦胶囊治疗,研究组在对照组基础上给予来氟米特片治疗。比较两组疗效,治疗前、治疗6周后两组的24h尿白蛋白(24h UAlb)、血肌酐(Scr)、血清尿素氮(BUN)、C反应蛋白(CRP);观察用药期间两组不良反应情况。结果:研究组总有效率为93.75%,明显高于对照组的79.17%,治疗后两组24h UAlb、Scr、BUN和CRP均较治疗前显著降低,研究组上述指标水平均明显低于对照组,差异有统计学意义;两组不良反应发生率比较差异无统计学意义。结论:来氟米特联合缬沙坦治疗糖尿病肾病,可提高疗效,显著减少尿蛋白的排出,降低血清Scr、BUN、CRP的水平,改善肾功能及临床症状,且较安全。

Objective:To study the clinical effect of the treatment of diabetic nephropathy by flumite combined with valsartan.Methods:96 cases of diabetic nephropathy were selected in our hospital from January 2015 to May 2017,and all patients were randomly divided into control group and research group,each 48 patients.Patients in the control group were treated with valsartan capsule,and patients in the research group were treated with flu-meter tablets based on the control group.Comparing curative effect,24 hours of albumin(24hUAlb),blood creatinine(Scr),serum urea nitrogen(BUN)and c-reactive protein(CRP)between the two groups before and after treatment for 6 weeks,and the adverse reactions between the two groups were observed during the observation.Results:The total effective rate of the research group was 93.75%,which was significantly higher than 79.17%of the control group,both groups of 24hUAlb,Scr,BUN and CRP were significantly lower after treatment than those before treatment,and the research group indicators were significantly lower than those in the control group,and the difference was statistically significant,there was no statistically significant difference between the two groups.Conclusion:Combination of fluorine mitt with valsartan therapy in patients with diabetic nephropathy can improve the curative effect,significantly reduce the discharge of urine protein,Scr,BUN,serum CRP levels,improve renal function and clinical symptoms,and safer.